Wnt signalling and the mechanistic basis of tumour development

Journal of Pathology

Volumn 205, Issue 2, 2005, Pages 130-144

  Ilyas, Mohammad ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

catenin; Tumourigenesis; Wnt signalling

Indexed keywords

APC PROTEIN; AXIN; BETA CATENIN; FRIZZLED PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; WNT PROTEIN;

BASAL CELL CARCINOMA; BLADDER CANCER; BREAST CANCER; CARCINOGENESIS; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; DOWN REGULATION; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; GENE ACTIVATION; GENE DISRUPTION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC MANIPULATION; GENETIC REGULATION; GENETIC TRANSCRIPTION; HEAD AND NECK CARCINOMA; HUMAN; INTESTINE CANCER; LIVER CANCER; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MALIGNANT TRANSFORMATION; MEDULLOBLASTOMA; MELANOMA; MESOTHELIOMA; MOLECULAR MECHANICS; MOUSE; NEPHROBLASTOMA; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; THYROID CANCER; TISSUE TYPES; UTERINE CERVIX CANCER;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; NEOPLASM PROTEINS; NEOPLASMS; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 13644269949     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1692     Document Type: Review

References (195)

1. Ilyas M, Straub J, Tomlinson IPM, Bodmer WF. Genetic pathways in colorectal and other cancers. Eur J Cancer 1999; 35: 335-351.
2. Vogelstein B, Kinzler KW. The Genetic Basis of Human Cancer (2nd edn). McGraw-Hill: New York, 2002.
3. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767.
4. Hainaut P, Soussi T, Shomer B, et al.. Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res 1997; 25: 151-157.
5. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor-suppressor gene - clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-4878.
6. Nusse R, Varmus HE. Many tumors induced by the mouse mammary-tumor virus contain a provirus integrated in the same region of the host genome. Cell 1982; 31: 99-109.
7. Vanooyen A, Nusse R. Structure and nucleotide-sequence of the putative mammary oncogene Int-1 - proviral insertions leave the protein-encoding domain intact. Cell 1984; 39: 233-240.
8. Nusse R, Vanooyen A, Cox D, Fung YKT, Varmus H. Mode of proviral activation of a putative mammary oncogene (Int-1) on mouse chromosome-15. Nature 1984; 307: 131-136.
9. Tsukamoto AS, Grosschedl R, Guzman RC, Parslow T, Varmus HE. Expression of the Int-1 gene in transgenic mice is associated with mammary-gland hyperplasia and adenocarcinomas in male and female mice. Cell 1988; 55: 619-625.
10. Rijsewijk F, Schuermann M, Wagenaar E, Parren P, Weigel D, Nusse R. The Drosophila homolog of the mouse mammary oncogene Int-1 is identical to the segment polarity gene Wingless. Cell 1987; 50: 649-657.
11. Nusse R, Brown A, Papkoff J, et al. A new nomenclature for Int-1 and related genes - the Wnt gene family. Cell 1991; 64 231-231.
12. McMahon AP. The Wnt family of developmental regulators. Trends Genet 1992; 8: 236-242.
13. Miller JR. The Wnts. Genome Biol 2002; 3(1): Reviews 3001.1-3001.15.
14. Liu PT, Wakamiya M, Shea MJ, Albrecht U, Behringer RR, Bradley A. Requirement for Wnt3 in vertebrate axis formation. Nature Genet 1999; 22: 361-365.
15. Ikeya M, Lee SMK, Johnson JE, McMahon AP, Takada S. Wnt signalling required for expansion of neural crest and CNS progenitors. Nature 1997; 389: 966-970.
16. Stark K, Vainio S, Vassileva G, McMahon AP. Epithelial transformation of metanephric mesenchyme in the developing kidney regulated by Wnt-4. Nature 1994; 372: 679-683.
17. Niemann S, Zhao CF, Pascu F, et al. Homozygous WNT3 mutation causes tetra-amelia in a large consanguineous family. Am J Hum Genet 2004; 74: 558-563.
18. Rodova M, Islam MR, Maser RL, Calvet JP. The polycystic kidney disease-1 promoter is a target of the beta-catenin/T-cell factor pathway. J Biol Chem 2002; 277: 29 577-29 583.
19. Jordan BK, Mohammed M, Ching ST, et al. Up-regulation of WNT-4 signaling and dosage-sensitive sex reversal in humans. Am J Hum Genet 2001; 68: 1102-1109.
20. He XC, Zhang J, Tong WG, et al. BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling. Nature Genet 2004; 36: 1117-1121.
21. Reya T, Duncan AW, Ailles L, et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 2003; 423: 409-414.
22. Ross SE, Hemati N, Longo KA, et al. Inhibition of adipogenesis by Wnt signaling. Science 2000; 289: 950-953.
23. Willert K, Brown JD, Danenberg E, et al. Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 2003; 423: 448-452.
24. Ingham PW. Has the quest for a Wnt receptor finally frizzled out? Trends Genet 1996; 12: 382-384.
25. YangSnyder J, Miller JR, Brown JD, Lai CJ, Moon RT. A frizzled homolog functions in a vertebrate Wnt signaling pathway. Curr Biol 1996; 6: 1302-1306.
26. Bhanot P, Brink M, Samos CH, et al. A new member of the frizzled family from Drosophila functions as a Wingless receptor. Nature 1996; 382: 225-230.
27. Huang HC, Klein PS. The Frizzled family: receptors for multiple signal transduction pathways. Genome Biol 2004; 5: 234.1-234.8.
28. Peifer M, Sweeton D, Casey M, Wieschaus E. Wingless signal and Zeste-White-3 kinase trigger opposing changes in the intracellular distribution of Armadillo. Development 1994; 120: 369-380.
29. Papkoff J, Rubinfeld B, Schryver B, Polakis P. Wnt-1 regulates free pools of catenins and stabilizes APC-catenin complexes. Mol Cell Biol 1996; 16: 2128-2134.
30. Veeman MT, Axelrod JD, Moon RT. A second canon: functions and mechanisms of beta-catenin-independent wnt signaling. Dev Cell 2003; 5: 367-377.
31. Axelrod JD, Miller JR, Shulman JM, Moon RT, Perrimon N. Differential recruitment of Dishevelled provides signaling specificity in the planar cell polarity and Wingless signaling pathways. Genes Dev 1998; 12: 2610-2622.
32. Boutros M, Mlodzik M. Dishevelled: at the crossroads of divergent intracellular signaling pathways. Mech Dev 1999; 83 27-37.
33. Boutros M, Paricio N, Strutt DI, Mlodzik M. Dishevelled activates JNK and discriminates between JNK pathways in planar polarity and wingless signaling. Cell 1998; 94: 109-118.
34. Jones SE, Jomary C. Secreted Frizzled-related proteins: searching for relationships and patterns. Bioessays 2002; 24: 811-820.
35. Hsieh JC, Kodjabachian L, Rebbert ML, et al. A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature 1999; 398: 431-436.
36. Piccolo S, Agius E, Leyns L, et al. The head inducer Cerberus is a multifunctional antagonist of Nodal, BMP and Wnt signals. Nature 1999; 397: 707-710.
37. Bell E, Munoz-Sanjuan I, Altmann CR, Vonica A, Brivanlou AH. Cell fate specification and competence by Coco, a maternal BMP, TGF beta and Wnt inhibitor. Development 2003; 130: 1381-1389.
38. Melkonyan HS, Chang WC, Shapiro JP, et al. SARPs: a family of secreted apoptosis-related proteins. Proc Natl Acad Sci U S A 1997; 94: 13 636-13 641.
39. Uren A, Reichsman F, Anest V, et al. Secreted frizzled-related protein-1 binds directly to wingless and is a biphasic modulator of Wnt signaling. J Biol Chem 2000; 275: 4374-4382.
40. Brott BK, Sokol SY. Regulation of Wnt/LRP signaling by distinct domains of Dickkopf proteins. Mol Cell Biol 2002; 22 6100-6110.
41. Fedi P, Bafico A, Soria AN, et al. Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling. J Biol Chem 1999; 274: 19465-19472.
42. Mao JH, Wang JY, Liu B, et al. Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. Mol Cell 2001; 7: 801-809.
43. Pinson KI, Brennan J, Monkley S, Avery BJ, Skarnes WC. An LDL-receptor-related protein mediates Wnt signalling in mice. Nature 2000; 407: 535-538.
44. Mao BY, Niehrs C. Kremen2 modulates Dickkopf2 activity during Wnt/LRP6 signaling. Gene 2003; 302: 179-183.
45. Mao BY, Wu W, Davidson G, et al. Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature 2002; 417: 664-667.
46. Mao BY, Wu W, Li Y, et al. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 2001; 411: 321-325.
47. Kikuchi A. Roles of axin in the Wnt signalling pathway. Cell Signalling 1999; 11: 777-788.
48. Hinoi T, Yamamoto H, Kishida M, Takada S, Kishida. S, Kikuchi A. Complex formation of adenomatous polyposis coli gene product and Axin facilitates glycogen synthase kinase-3 beta-dependent phosphorylation of beta-catenin and down-regulates beta-catenin. J Biol Chem 2000; 275: 34 399-34 406.
49. Ikeda S, Kishida M, Matsuura Y, Usui H, Kikuchi A. GSK-3 beta-dependent phosphorylation of adenomatous polyposis coli gene product can be modulated by beta-catenin and protein phosphatase 2A complexed with Axin. Oncogene 2000; 19: 537-545.
50. Yamamoto H, Kishida S, Kishida M, Ikeda S, Takada S, Kikuchi A. Phosphorylation of Axin, a Wnt signal negative regulator, by glycogen synthase kinase-3 beta regulates its stability. J Biol Chem 1999; 274: 10681-10684.
51. Kishida S, Yamamoto H, Ikeda S, et al. Communication - Axin, a negative regulator of the Wnt signaling pathway, directly interacts with adenomatous polyposis coli and regulates the stabilization of beta-catenin. J Biol Chem 1998; 273: 10 823-10 826.
52. Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S, Kikuchi A. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3 beta and beta-catenin and promotes GSK-3 beta-dependent phosphorylation of beta-catenin. EMBO J 1998; 17: 1371-1384.
53. Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, Polakis P. Binding of GSK3 beta to the APC-beta-catenin complex and regulation of complex assembly. Science 1996; 272: 1023-1026.
54. Rubinfeld B, Souza B, Albert I, et al. Association of the Apc gene-product with beta-catenin. Science 1993; 262: 1731-1734.
55. Sakanaka C, Weiss JB, Williams LT. Bridging of beta-catenin and glycogen synthase kinase-3 beta by Axin and inhibition of beta-catenin-mediated transcription. Proc Natl Acad Sci U S A 1998; 95: 3020-3023.
56. Seeling JM, Miller JR, Gil R, Moon RT, White R, Virshup DM. Regulation of beta-catenin signaling by the B56 subunit of protein phosphatase 2A. Science 1999; 283: 2089-2091.
57. Liu CM, Li YM, Semenov M, et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002; 108: 837-847.
58. Latres E, Chiaur DS, Pagano M. The human F box protein beta-Trcp associates with the Cull/Skp1 complex and regulates the stability of beta-catenin. Oncogene 1999; 18: 849-854.
59. Hart M, Concordet JP, Lassot I, et al. The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr Biol 1999; 9: 207-210.
60. Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 1998; 17: 7151-7160.
61. Matsuzawa S, Reed JC. Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses. Mol Cell 2001; 7: 915-926.
62. Liu J, Stevens J, Rote CA, et al. Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. Mol Cell 2001; 7: 927-936.
63. Sadot E, Geiger B, Oren M, Ben-Ze'ev A. Down-regulation of beta-catenin by activated p53. Mol Cell Biol 2001; 21: 6768-6781.
64. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004; 303: 1483-1487.
65. Ilyas M, Tomlinson IPM. The interactions of APC, E-cadherin and beta-catenin in tumour development and progression. J Pathol 1997; 182: 128-137.
66. 2-terminal truncated beta-catenin on mouse intestinal epithelial homeostasis. J Cell Biol 1998; 141: 765-777.
67. Brunner E, Peter O, Schweizer L, Basler K. pangolin encodes a Lef-1 homologue that acts downstream of Armadillo to transduce the Wingless signal in Drosophila. Nature 1997; 385: 829-833.
68. Behrens J, von Kries JP, Kuhl M, et al. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 1996; 382: 638-642.
69. Brantjes H, Barker N, van Es J, Clevers H. TCF: lady justice casting the final verdict on the outcome of Wnt signalling. Biol Chem 2002; 383: 255-261.
70. Cavallo RA, Cox RT, Moline MM, et al. Drosophila Tcf and Groucho interact to repress Wingless signalling activity. Nature 1998; 395: 604-608.
71. Roose J, Molenaar M, Peterson J, et al. The Xenopus Wnt effector XTcf-3 interacts with Groucho-related transcriptional repressors. Nature 1998; 395: 608-612.
72. Takemaru KI, Yamaguchi S, Lee YS, Zhang Y, Carthew RW, Moon RT. Chibby, a nuclear beta-catenin-associated antagonist of the Wnt/Wingless pathway. Nature 2003; 422: 905-909.
73. Topol L, Jiang XY, Choi H, Garrett-Beal L, Carolan PJ, Yang YZ. Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent beta-catenin degradation. J Cell Biol 2003; 162: 899-908.
74. van den Brink GR, Bleuming SA, Hardwick JCH, et al. Indian Hedgehog is an antagonist of Wnt signaling in colonic epithelial cell differentiation. Nature Genet 2004; 36: 277-282.
75. Kishida M, Hino S, Michiue T, et al. Synergistic activation of the Wnt signaling pathway by Dvl and casein kinase I epsilon. J Biol Chem 2001; 276: 33 147-33 155.
76. Lee E, Salic A, Kirschner MW. Physiological regulation of β-catenin stability by Tcf3 and CK1 epsilon. J Cell Biol 2001; 154: 983-993.
77. Fagotto F, Gluck U, Gumbiner BM. Nuclear localization signal-independent and importin/karyopherin-independent nuclear import of beta-catenin. Curr Biol 1998; 8: 181-190.
78. Rosin-Arbesfeld R, Townsley F, Bienz M. The APC tumour suppressor has a nuclear export function. Nature 2000; 406: 1009-1012.
79. Neufeld KL, Nix DA, Bogerd H, et al. Adenomatous polyposis coli protein contains two nuclear export signals and shuttles between the nucleus and cytoplasm. Proc Natl Acad Sci U S A 2000; 97: 12 085-12 090.
80. Neufeld KL, Zhang F, Cullen BR, White RL. APC-mediated downregulation of beta-catenin activity involves nuclear sequestration and nuclear export. EMBO Rep 2000; 1: 519-523.
81. Townsley FM, Cliffe A, Bienz M. Pygopus and Legless target Armadillo/beta-catenin to the nucleus to enable its transcriptional co-activator function. Nature Cell Biol 2004; 6: 626-633.
82. Graham NA, Asthagiri AR. Epidermal growth factor-mediated T-cell factor/lymphoid enhancer factor transcriptional activity is essential but not sufficient for cell cycle progression in nontransformed mammary epithelial cells. J Biol Chem 2004; 279: 23 517-23 524.
83. Danilkovitch-Miagkova A, Miagkov A, Skeel A, Nakaigawa N, Zbar B, Leonard EJ. Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the beta-catenin pathway. Mol Cell Biol 2001; 21: 5857-5868.
84. Bonvini P, An WG, Rosolen A, et al. Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription. Cancer Res 2001; 61: 1671-1677.
85. Eger A, Stockinger A, Park J, et al. Beta-catenin and TGF beta signalling cooperate to maintain a mesenchymal phenotype after FosER-induced epithelial to mesenchymal transition. Oncogene 2004; 23: 2672-2680.
86. Morali OG, Delmas V, Moore R, Jeanney C, Thiery JP, Larue L. IGF-II induces rapid beta-catenin relocation to the nucleus during epithelium to mesenchyme transition. Oncogene 2001; 20: 4942-4950.
87. Desbois-Mouthon C, Cadoret A, Blivet-Van Eggelpoel MJ, et al. Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3 beta inhibition and Ras activation. Oncogene 2001; 20: 252-259.
88. Playford MP, Bicknell D, Bodmer WF, Macaulay VM. Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of beta-catenin. Proc Natl Acad Sci U S A 2000; 97: 12 103-12 108.
89. D'Amico M, Hulit J, Amanatullah DF, et al. The integrin-linked kinase regulates the cyclin D1 gene through glycogen synthase kinase 3 beta and cAMP-responsive element-binding protein-dependent pathways. J Biol Chem 2000; 275: 32 649-32 657.
90. Novak A, Hsu SC, Leung-Hagesteijn C, et al. Cell adhesion and the integrin-linked kinase regulate the LEF-1 and beta-catenin signaling pathways. Proc Natl Acad Sci U S A 1998; 95: 4374-4379.
91. Morrison JA, Gulley ML, Pathmanathan R, Raab-Traub N. Differential signaling pathways are activated in the Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma. Cancer Res 2004; 64: 5251-5260.
92. Morrison JA, Klingelhutz AJ, Raab-Traub N. Epstein-Barr virus latent membrane protein 2A activates beta-catenin signaling in epithelial cells. J Virol 2003; 77: 12 276-12 284.
93. Kramps T, Peter O, Brunner E, et al. Wnt/Wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear beta-catenin-TCF complex. Cell 2002; 109: 47-60.
94. Roose J, Clevers H. TCF transcription factors: molecular switches in carcinogenesis. Biochim Biophys Acta - Rev Cancer 1999; 1424: M23-M37.
95. Sansom OJ, Reed KR, Hayes AJ, et al. Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation, and migration. Genes Dev 2004; 18: 1385-1390.
96. Paoni NF, Feldman MW, Gutierrez LS, Ploplis VA, Castellino FJ. Transcriptional profiling of the transition from normal intestinal epithelia to adenomas and carcinomas in the APC(Min/+) mouse. Physiol Genomics 2003; 15: 228-235.
97. Chen TA, Yang I, Irby R, et al. Regulation of caspase expression and apoptosis by adenomatous polyposis coli. Cancer Res 2003; 63: 4368-4374.
98. van de Wetering M, Sancho E, Verweij C, et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002; 111: 241-250.
99. Kim JS, Crooks H, Dracheva T, et al. Oncogenic beta-catenin is required for bone morphogenetic protein 4 expression in human cancer cells. Cancer Res 2002; 62: 2744-2748.
100. Mann B, Gelos M, Siedow A, et al. Target genes of beta-catenin-T cell-factor lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci U S A 1999; 96: 1603-1608.
101. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science 1998; 281: 1509-1512.
102. Blache P, van de Wetering M, Duluc I, et al. SOX9 is an intestine crypt transcription factor, is regulated by the Wnt pathway, and represses the CDX2 and MUC2 genes. J Cell Biol 2004; 166: 37-47.
103. Weeraratna AT, Jiang YA, Hostetter G, et al. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 2002; 1: 279-288.
104. Jonsson M, Dejmek J, Bendahl PO, Andersson T. Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas. Cancer Res 2002; 62: 409-416.
105. Korinek V, Barker N, Morin PJ, et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC(-/-) colon carcinoma. Science 1997; 275: 1784-1787.
106. Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275: 1787-1790.
107. Polakis P. The adenomatous polyposis coli (APC) tumor suppressor. Biochim Biophys Acta - Rev Cancer 1997; 1332: F127-F147.
108. Nakamura Y. The role of the adenomatous polyposis-coli (Apc) gene in human cancers. Adv Cancer Res 1993; 62: 65-87.
109. Rowan AJ, Lamlum H, Ilyas M, et al. APC mutations in sporadic colorectal tumors: a mutational 'hotspot' and interdependence of the 'two hits'. Proc Natl Acad Sci U S A 2000; 97: 3352-3357.
110. Samowitz WS, Powers MD, Spirio LN, Nollet F, van Roy F, Slattery ML. Beta-catenin mutations are more frequent in small colorectal adenomas than in larger adenomas and invasive carcinomas. Cancer Res 1999; 59: 1442-1444.
111. Harada N, Tamai Y, Ishikawa T, et al. Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. EMBO J 1999; 18: 5931-5942.
112. Harada N, Miyoshi H, Murai N, et al. Lack of tumorigenesis in the mouse liver after adenovirus-mediated expression of a dominant stable mutant of beta-catenin. Cancer Res 2002; 62 1971-1977.
113. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
114. Korinek V, Barker N, Moerer P, et al. Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nature Genet 1998; 19: 379-383.
115. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398: 422-426.
116. Marchenko ND, Marchenko GN, Weinreb RN, et al. Beta-catenin regulates the gene of MMP-26, a novel matrix metalloproteinase expressed both in carcinomas and normal epithelial cells. Int J Biochem Cell Biol 2004; 36: 942-956.
117. Takahashi M, Tsunoda T, Seiki M, Nakamura Y, Furukawa Y. Identification of membrane-type matrix metalloproteinase-1 as a target of the beta-catenin/Tcf4 complex in human colorectal cancers. Oncogene 2002; 21: 5861-5867.
118. Brabletz T, Jung A, Dag S, Hlubek F, Kirchner T. Beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol 1999; 155: 1033-1038.
119. Coussens LM, Fingleton B, Matrisian LM. Cancer therapy - matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387-2392.
120. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nature Rev Cancer 2002; 2: 161-174.
121. Zhang XB, Gaspard JP, Chung DC. Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res 2001; 61: 6050-6054.
122. Agnihotri R, Crawford HC, Haro H, Matrisian LM, Havrda MC, Liaw L. Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol Chem 2001; 276: 28 261-28 267.
123. Leow CC, Romero MS, Ross S, Polakis P, Gao WQ. Hath1, down-regulated in colon adenocarcinomas, inhibits proliferation and tumorigenesis of colon cancer cells. Cancer Res 2004; 64: 6050-6057.
124. Browning M, Petronzelli F, Bicknell D, et al. Mechanisms of loss of HLA class I expression on colorectal tumor cells. Tissue Antigens 1996; 47: 364-371.
125. Suzuki H, Watkins DN, Jair KW, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nature Genet 2004; 36: 417-422.
126. Kim JS, Crooks H, Foxworth A, Waldman T. Proof-of-principle: oncogenic beta-catenin is a valid molecular target for the development of pharmacological inhibitors. Mol Cancer Ther 2002; 1: 1355-1359.
127. Chan TA, Wang ZH, Dang LH, Vogelstein B, Kinzler KW. Targeted inactivation of CTNNB1 reveals unexpected effects of beta-catenin mutation. Proc Natl Acad Sci U S A 2002; 99: 8265-8270.
128. Gunther EJ, Moody SE, Belka GK, et al. Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev 2003; 17: 488-501.
129. Yu QY, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001; 411: 1017-1021.
130. Wilding J, Straub J, Bee J, et al. Cyclin D1 is not an essential target of beta-catenin signaling during intestinal tumorigenesis, but it may act as a modifier of disease severity in multiple intestinal neoplasia (Min) mice. Cancer Res 2002; 62 4562-4565.
131. You L, He B, Xu ZD, et al. Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene 2004; 23: 6170-6174.
132. Lu DS, Zhao YD, Tawatao R, et al. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2004; 101: 3118-3123.
133. Kim JM, Sohn HY, Oh JH, Kim JG, Kim NS, Kim YS. Characterization of human WNT7b gene and its up regulation in gastric cancer cell lines. Exp Oncol 2003; 25: 211-215.
134. Saitoh T, Mine T, Katoh M. Frequent up-regulation of WNT5A mRNA in primary gastric cancer. Int J Mol Med 2002; 9: 515-519.
135. Rhee CS, Sen M, Lu DS, et al. Wnt and frizzled receptors as potential targets for immunotherapy in head and neck squamous cell carcinomas. Oncogene 2002; 21: 6598-6605.
136. Holcombe RF, Marsh JL, Waterman ML, Lin F, Milovanovic T, Truong T. Expression of Wnt ligands and Frizzled receptors in colonic mucosa and in colon carcinoma. J Clin Pathol - Mol Pathol 2002; 55: 220-226.
137. Ricken A, Lochhead P, Kontogiannea M, Farookhi R. Wnt signaling in the ovary: identification and compartmentalized expression of wnt-2, wnt-2b, and frizzled-4 mRNAs. Endocrinology 2002; 143 2741-2749.
138. Lo Muzio L, Pannone G, Staibano S, et al. WNT-1 expression in basal cell carcinoma of head and neck. An immunohistochemical and confocal study with regard to the intracellular distribution of beta-catenin. Anticancer Res 2002; 22: 565-576.
139. Klopocki E, Kristiansen G, Wild PJ, et al. Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int J Oncol 2004; 25: 641-649.
140. Ugolini F, Charafe-Jauffret E, Bardou VJ, et al. WNT pathway and mammary carcinogenesis: loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type. Oncogene 2001; 20: 5810-5817.
141. Stoehr R, Wissmann C, Suzuki H, et al. Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab Invest 2004; 84: 465-478.
142. Lee AY, He B, You L, et al. Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma. Oncogene 2004; 23: 6672-6676.
143. Caldwell GM, Jones C, Gensberg K, et al. The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res 2004; 64: 883-888.
144. Wissmann C, Wild PJ, Kaiser S, et al. WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol 2003; 201: 204-212.
145. Mazieres J, He B, You L, et al. Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res 2004; 64: 4717-4720.
146. Hoang BH, Kubo T, Healey JH, et al. Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer 2004; 109 106-111.
147. Tanaka S, Akiyoshi T, Mori M, Wands JR, Sugimachi K. A novel frizzled gene identified in human esophageal carcinoma mediates APC/beta-catenin signals. Proc Natl Acad Sci U S A 1998; 95: 10 164-10 169.
148. Kirikoshi H, Sekibara H, Katoh M. Up-regulation of Frizzled-7 (FZD7) in human gastric cancer. Int J Oncol 2001; 19: 111-115.
149. Nagahata T, Shimada T, Harada A, et al. Amplification, up-regulation and over-expression of DVL-1, the human counterpart of the Drosophila disheveled gene, in primary breast cancers. Cancer Sci 2003; 94: 515-518.
150. Uematsu K, Kanazawa S, You L, et al.. Wnt pathway activation in mesothelioma: evidence of dishevelled overexpression and transcriptional activity of beta-catenin. Cancer Res 2003; 63 4547-4551.
151. Okino K, Nagai H, Hatta M, et al. Up-regulation and overproduction of DVL-1, the human counterpart of the Drosophila dishevelled gene, in cervical squamous cell carcinoma. Oncol Rep 2003; 10: 1219-1223.
152. Saitoh T, Mine T, Katoh M. Molecular cloning and expression of proto-oncogene FRAT1 in human cancer. Int J Oncol 2002; 20 785-789.
153. Saitoh T, Katoh M. FRAT1 and FRAT2, clustered in human chromosome 10q24.1 region, are up-regulated in gastric cancer. Int J Oncol 2001; 19: 311-315.
154. Clements WM, Wang J, Sarnaik A, et al. Beta-catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer. Cancer Res 2002; 62: 3503-3506.
155. Park WS, Oh RR, Park JY, et al. Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer. Cancer Res 1999; 59: 4257-4260.
156. Ilyas M, Tomlinson IPM, Rowan A, Pignatelli M, Bodmer WF. Beta-catenin mutations in cell lines established from human colorectal cancers. Proc Natl Acad Sci U S A 1997; 94: 10 330-10 334.
157. Fujimori M, Ikeda S, Shimizu Y, Okajima M, Asahara T. Accumulation of beta-catenin protein and mutations in exon 3 of beta-catenin gene in gastrointestinal carcinoid tumor. Cancer Res 2001; 61: 6656-6659.
158. Gamallo C, Palacios J, Moreno G, de Mora JC, Suarez A, Armas A. Beta-catenin expression pattern in stage I and II ovarian carcinomas - relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol 1999; 155: 527-536.
159. Wu R, Zhai Y, Fearon ER, Cho KR. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res 2001; 61: 8247-8255.
160. Sunaga N, Kohno T, Kolligs FT, Fearon ER, Saito R, Yokota J. Constitutive activation of the Wnt signaling pathway by CTNNB1 (beta-catenin) mutations in a subset of human lung adenocarcinoma. Genes Chromosomes Cancer 2001; 30: 316-321.
161. Fukuchi T, Sakamoto M, Tsuda H, Maruyama K, Nozawa S, Hirohashi S. Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res 1998; 58: 3526-3528.
162. Kobayashi K, Sagae S, Nishioka Y, Tokino T, Kudo R. Mutations of the beta-catenin gene in endometrial carcinomas. Jpn J Cancer Res 1999; 90: 55-59.
163. Mirabelli-Primdahl L, Gryfe R, Kim H, et al. Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res 1999; 59: 3346-3351.
164. Satoh S, Daigo Y, Furukawa Y, et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nature Genet 2000; 24: 245-250.
165. Wong CM, Fan ST, Ng IOL. Beta-catenin mutation and overexpression in hepatocellular carcinoma - clinicopathologic and prognostic significance. Cancer 2001; 92: 136-145.
166. Koch A, Denkhaus D, Albrecht S, Leuschner I, von Schweinitz D, Pietsch T. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Cancer Res 1999; 59: 269-273.
167. Koch A, Waha A, Tonn JC, et al. Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors. Int J Cancer 2001; 93: 445-449.
168. Abraham SC, Klimstra DS, Wilentz: RE, et al. Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. Am J Pathol 2002; 160: 1361-1369.
169. Garcia-Rostan G, Tallini G, Herrero A, D'Aquila TG, Carcangiu ML, Rimm DL. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res 1999; 59: 1811-1815.
170. Garcia-Rostan G, Camp RL, Herrero A, Carcangiu ML, Rimm DL, Tallini G. Beta-catenin dysregulation in thyroid neoplasms - down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol 2001; 158: 987-996.
171. Chesire DR, Ewing CM, Sauvageot J, Bova GS, Isaacs WB. Detection and analysis of beta-catenin mutations in prostate cancer. Prostate 2000; 45: 323-334.
172. Voeller HJ, Truica CI, Gelmann EP. Beta-catenin mutations in human prostate cancer. Cancer Res 1998; 58: 2520-2523.
173. Reifenberger J, Knobbe CB, Wolter M, et al. Molecular genetic analysis of malignant melanomas for aberrations of the Wnt signaling pathway genes CTNNB1, APC, ICAT and BTRC. Int J Cancer 2002; 100: 549-556.
174. Chan EF, Gat U, McNiff JM, Fuchs E. A common human skin tumour is caused by activating mutations in beta-catenin. Nature Genet 1999; 21: 410-413.
175. Koesters R, Niggli F, Doeberitz MV, Stallmach T. Nuclear accumulation of beta-catenin protein in Wilms' tumours. J Pathol 2003; 199: 68-76.
176. Abraham SC, Wu TT, Klimstra DS, et al. Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposis-associated pancreatoblastomas - frequent alterations in the APC/beta-catenin pathway and chromosome 11p. Am J Pathol 2001; 159: 1619-1627.
177. Sakamoto A, Oda Y, Adachi T, et al. Beta-catenin accumulation and gene mutation in exon 3 in dedifferentiated liposarcoma and malignant fibrous histiocytoma. Arch Pathol Lab Med 2002; 126: 1071-1078.
178. Abraham SC, Montgomery EA, Giardiello FM, Wu TT. Frequent beta-catenin mutations in juvenile nasopharyngeal angiofibromas. Am J Pathol 2001; 158: 1073-1078.
179. Tejpar S, Nollet F, Li C, et al. Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene 1999; 18: 6615-6620.
180. Miyoshi Y, Iwao K, Nawa G, Yoshikawa H, Ochi T, Nakamura Y. Frequent mutations in the beta-catenin gene in desmoid tumors from patients without familial adenomatous polyposis. Oncol Res 1998; 10: 591-594.
181. Saito T, Oda Y, Sakamoto A, et al. Prognostic value of the preserved expression of the E-cadherin and catenin families of adhesion molecules and of beta-catenin mutations in synovial sarcoma. J Pathol 2000; 192: 342-350.
182. Rubinfeld B, Robbins P, El Gamil M, Albert I, Porfiri E, Polakis P. Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 1997; 275: 1790-1792.
183. Huang HT, Mahler-Araujo BM, Sankila A, et al. APC mutations in sporadic medulloblastomas. Am J Pathol 2000; 156 433-437.
184. Alman BA, Li C, Pajerski ME, Diaz Cano S, Wolfe HJ. Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am J Pathol 1997; 151: 329-334.
185. Taniguchi K, Roberts LR, Aderca IN, et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 2002; 21: 4863-4871.
186. Dahmen RP, Koch A, Denkhaus D, et al. Deletions of AXIN1, a component of the WNT/wingless pathway, in sporadic medulloblastomas. Cancer Res 2001; 61: 7039-7043.
187. Yokota N, Nishizawa S, Ohta S, et al. Role of Wnt pathway in medulloblastoma oncogenesis. Int J Cancer 2002; 101 198-201.
188. He TC, Chan TA, Vogelstein B, Kinzler KW. PPAR delta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999; 99: 335-345.
189. Koh TJ, Bulitta CJ, Fleming JV, Dockray GJ, Varro A, Wang TC. Gastrin is a target of the beta-catenin/TCF-4 growth-signaling pathway in a model of intestinal polyposis. J Clin Invest 2000; 106: 533-539.
190. Wielenga VJM, Smits R, Korinek V, et al. Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol 1999; 154: 515-523.
191. Miwa N, Furuse M, Tsukita S, Niikawa N, Nakamura Y, Furukawa Y. Involvement of claudin-1 in the beta-catenin/Tcf signaling pathway and its frequent upregulation in human colorectal cancers. Oncol Res 2001; 12: 469-476.
192. Zhang T, Otevrel T, Gao ZQ, et al. Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 2001; 61: 8664-8667.
193. Boon EMJ, van der Neut R, van de Wetering M, Clevers H, Pals ST. Wnt signaling regulates expression of the receptor tyrosine kinase Met in colorectal cancer. Cancer Res 2002; 62: 5126-5128.
194. Howe LR, Subbaramaiah K, Chung WJ, Dannenberg AJ, Brown AMC. Transcriptional activation of cyclooxygenase-2 in Wnt-1-transformed mouse mammary epithelial cells. Cancer Res 1999; 59: 1572-1577.
195. Batlle E, Henderson JT, Beghtel H, et al. Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/EphrinB. Cell 2002; 111: 251-263.